WWW.AHUSALLIANCEGLOBALACTION.ORG 18 March 2023 aHUS PATIENTS' VIEWS ON THE ATTRIBUTION OF ADVERSE EVENTS /SIDE EFFECTS EXPERIENCED DUE TO EITHER THEIR PRIMARY DISEASE OR ITS TREATMENT Amber, Amelie, Amy, Anne-Kathrin, Arthur,…
Jump to Section: About aHUS | Special Events | Clinical Information | Networks and Support | Patient Materials (to Print & Share) |aHUS Global Advocate: NEWSLETTER |aHUS alliance Global Action…
To answer some of the questions in the aHUS Patients Research Agenda clinical trials will be needed. Take the issue of withdrawal from complement inhibitor treatment. Setting up a trial…
Fund raising, which began when aHUSUK still existed, has been put to use to help fund research which may improve the aHUS diagnosis process. Readers of this website may have…
We’re pleased to feature this interview with Dr Brad Lewis, Medical Director of Machaon Diagnostics. A hematologist with background in biochemistry and focus on thrombosis and hemostasis, Dr Lewis lectures…
Ravulizumab is eculizumab, Carsten. They work the same way. It is the same monoclonal antibody. It has just been modified in a couple of places so that it is effective…
When Jeff, the producer of these awareness day videos, suggested that "questions" should be the theme of this years' RDD Video I was surprised. Surprised because it had been five…
Article No. 457 Yet another article about the outcome of withdrawal of eculizumab treatment has appeared. It is not about a controlled trial of patients selected to test withdrawal of…